The Pulmonary-Allergy Drugs Advisory Committee will meet tomorrow to discuss InterMune's idiopathic pulmonary fibrosis candidate pirfenidone, a product FDA staffers expressed concern about in briefing documents. FDA reviewers said only one of the company's two key trials showed efficacy, and "the clinical significance of the treatment effect size is uncertain." Despite the agency's concerns, investors who were braced for a more negative analysis sent the company's shares soaring Friday. Report